| Literature DB >> 33683297 |
Kexin Li1, Xue Feng1, Kenji Hikosaka1, Kazumi Norose1.
Abstract
Purpose: To establish a murine model of primary acquired ocular toxoplasmosis (OT) and to investigate the immune mediator profiles in the aqueous humor (AH).Entities:
Year: 2021 PMID: 33683297 PMCID: PMC7960860 DOI: 10.1167/iovs.62.3.9
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.799
Figure 1.Representative ophthalmic observations. Panels A, B, and C show mouse nos. 13, 14, and 3, respectively. The upper parts of A, B, and C show fundus photographs, and the lower panels show fluorescein angiograms. Images a and d of panels A and B, and images a and c of panel C show mice before infection with T. gondii. Images b and e of panels A and B were taken at 14 dpi. Images c and f of panels A and B, and images b, d, and e of panel C were taken at 28 dpi. The black arrows in the fundus photographs and the white arrows in fluorescein angiogram images show different views of the same lesions. (A) The dense exudative lesion (black arrow) in image b shows active retinochoroiditis initially characterized by soft, small, multifocal, individual, slightly white-gray discolorations of the fundus. Image e shows the leakage of fluorescein dye (white arrow) from the area of this dense exudative lesion in image b. The exudative retinochoroiditis seen in image b became smaller and harder over time, as seen in image c (black arrow). The many hard white areas in image c (black arrowheads) indicate inactive lesions. Image f shows no further fluorescein leakage (white arrow). (B) The soft exudative lesions in image b indicate active lesions (arrowhead). The retinal vein was dilated and tortuous (black arrow). Image e shows a clear view of the dilatation and tortuosity of the retinal vein and fluorescein dye leakage (white arrow). Image c shows a less-dilated and less-tortuous retinal vein (black arrow) and many hard foci, indicating inactive lesions (black arrowheads). Image f shows a slightly less dilated and less tortuous vein compared with image e, indicating the inactive phase (white arrow). Because image d was taken without an excitation filter, the image was converted into grayscale. (C) The soft exudative lesions in image b are areas of active retinochoroiditis (black arrow). Hard white lesions indicate inactive lesions (black arrowheads). Image d shows a hyperfluorescent area indicating a disruption of the blood–retinal barrier at early phase (white arrow). Image e, taken 2 minutes, 32 seconds after image d, shows enlarged fluorescein leakage (white arrow).
Figure 2.Histological and immunohistochemical findings at 0 and 28 dpi. Representative images of eye (A–L) and brain (M–P) sections. (A) Whole eye from an uninfected mouse. (B) Retina of an uninfected mouse eye. No infiltration of inflammatory cells was detected in the uninfected eyes. (C) Inflammatory cells were seen in the anterior chamber (black arrows). (D) Numerous inflammatory cells were present in the vitreous (black arrows). (E) Higher magnification image of the section shown in panel D. (F) Retinal vasculitis (black arrowhead), retinal fold (black arrow), and a subretinal granuloma (black star). The retina was edematous. Retinal degeneration, cellular layer disorganization, and subretinal granulomatous inflammation overlying the choroiditis foci were common, as were retinal pigment epithelium hyperplasia and hypertrophy. (G) Vasculitis was evident (black arrowhead). (H) An area of retinitis with accumulation of inflammatory cells and disorganization of the retinal architecture. Pigment migration into the retina (black star). (I) Higher magnification image of the section shown in H. Pigment migration into the sensory retina (black star). (J) Toxoplasma cyst present in the inner nuclear layer, with no host reaction (black arrow). (K) Higher-magnification image of the section shown in panel J; note the many tiny nuclei in the cyst (black arrow). (L) Toxoplasma cyst in the inner plexiform layer (white arrow) detected with immunohistochemistry using anti-T. gondii antibody (green) and Dolichos-binding lectin (red; cyst wall). (M) Brain from an uninfected mouse. The insert shows a blood vessel. (N) Infiltration of inflammatory cells in the brain (black arrows). (O) Vasculitis in the brain (black arrow). (P) Toxoplasma cyst (black arrow) filled with bradyzoites in the brain. A–K and M–P: Hematoxylin & eosin stain. Scale bars: 100 µm (A); 10 µm (B–P).
Figure 3.In vivo cytokine and chemokine production in the aqueous humor (AH), cerebral spinal fluid (CSF), and serum. Cytokine and chemokine levels were determined using a Bio-Plex Assay. Th1 (A), Th2 and Treg (B), and Th17 (C) cytokine profiles. (D) Chemokine and proinflammatory growth factor profiles. Values are the means ± SD of 3 independent experiments. Samples from 6 mice were pooled. White bars, uninfected mice; black bars, infected mice. * and ** show significant differences with P < 0.05 and P < 0.01, respectively, between uninfected and infected mice. + and ++ show significant differences with P < 0.05 and P < 0.01, respectively, between the AH and CSF, AH and serum, and CSF and serum of uninfected (dotted line) or infected (solid line) mice.
Cytokine and Chemokine Levels in the Aqueous Humor, Cerebral Spinal Fluid, and Serum
| Toxoplasmosis | Viral uveitis/ARN | IU | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse (this study) | Mouse (other studies) | Human (other studies) | Human | Human | |||||||
| Group | AH | CSF | Serum | AH | CSF | Serum | AH | CSF | Serum | AH | AH |
| Type 1 cytokines | |||||||||||
| IFN-γ | ↑ | ↑ | N.S. | ↑41, 45 | ↑22, 24, 25 | ↑ 23, 24, 46, 63, 64 ↑ then ↓ 22, 62, 66 | ↑ 36, 37, 38, 40, 41, 42, 43, 43 | N.S. 61 | ↑ then ↓ 44 N.S. 44, 61 | ↑ 33, 36, 38, 40 N.S. 31, 35 | ↑ 31, 38 N.S. 34 |
| IL-12(p40) | ↑ | ↑ | ↑ | ↑45 | ↑25, 64 | ↑36 | ↑61 | ↑ 61 | N.S. 36 | ↓ 34 | |
| IL-12(p70) | ↑ | ↑ | N.S. | ↑ 48 N.S. 48 | ↑67 | ↑42 N.S. 37, 38, 43, 43 | ↑ 38 ↓ 31 N.S. 35 | ↓ 31 N.S. 38 | |||
| TNF-α | N.S. | ↑ | N.S. | ↑41, 47, 47 | ↑22 | ↑22 | ↑36, 37, 42, 43, 43 | ↑ then ↓ 44 N.S. 44, 78 | ↑36 N.S. 33, 35, 38 | ↓34 N.S. 38 | |
| IL-2 | N.D. | N.D. | N.D. | ↑ 41, 47, 48 ↑ then ↓ 47 | ↑ 36, 40ǁ, 41, 42, 43, 43 | ↑ then ↓ 44 N.S. 44, 78 | ↑ 38 ↓ 31 N.S. 33, 35, 36, 40 | ↑ 38 ↓ 31, 34 | |||
| Type 2 cytokines | |||||||||||
| IL-3 | N.D. | N.D. | N.S. | ||||||||
| IL-4 | N.S. | ↑ | N.S. | ↑ 48 N.S. 48 N.D. 46 | ↑63 N.D. 46 | ↑36, 37, 42, 43, 43 | ↑ then ↓ 44 N.S. 44 | ↑ 36, 38 N.S. 33, 35, 40 | ↑ 38 | ||
| IL-5 | N.S. | N.S. | N.S. | ↑ 48 | ↑36, 38, 42, 43, 43 | ↑36, 38 N.S. 33, 35 | ↑ 38 | ||||
| IL-9 | N.S. | N.S. | N.S. | ↑ 43, 43 | N. S. 38 | ↑ 34 N.S. 38 | |||||
| IL-10 | ↑ | ↑ | N.S. | ↑41, 47, 47 | ↑25 | ↑64 ↓46, 63 | ↑ 36, 40, 41, 42 N.S. 37, 38, 42, 43, 43 | ↑ then ↓ 44 N.S. 44, 78 | ↑ 31, 33, 35, 36, 38, 40 | N.S. 31, 34, 38 | |
| IL-13 | N.S. | ↑ | N.S. | ↑41, 47, 47 | ↑36, 37, 41, 42, 43 N.S. 38, 42, 43 | ↑ 36, 38 ↓ 31 N.S. 35 | ↑ 38 ↓ 31 | ||||
Continued
| Toxoplasmosis | Viral uveitis/ARN | IU | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mouse (this study) | Mouse (other studies) | Human (other studies) | Human | Human | |||||||
| Group | AH | CSF | Serum | AH | CSF | Serum | AH | CSF | Serum | AH | AH |
| Th17 cytokines | |||||||||||
| IL-17A | N.S. | N.S. | ↓ | ↑ 41 | ↑36 | N. S. 35, 36 | N.S. 38 | ||||
| IL-1α | ↑ | N.S. | N.S. | ↑ 48 N.S. 48 | ↑63 | ||||||
| IL-1β | ↑ | ↑ | N.S. | ↑ 48 N.S. 48 | ↑36, 42, 43, 43 | ↑ then ↓ 44 N.S. 44, 78 | ↑36, 38 N.S. 35 | N.S. 38 | |||
| IL-6 | ↑ | ↑ | N.S. | ↑ 41, 45 | ↑22, 25 | ↑ 46, 63, 67 ↑ then ↓ 22, 66 | ↑36, 37, 38, 39, 40, 41, 42, 43, 43 | ↑21 | ↑ then ↓ 44 N.S. 39, 44, 78 | ↑ 35, 36, 38, 40 N.S. 31 | ↑ 31, 34, 38 |
| Chemokines and growth factors | |||||||||||
| CCL2/MCP-1 | ↑ | ↑ | N.S. | ↑41, 45 | ↑ 25 | ↑ 67 ↑ then ↓ 62 | ↑36, 37, 38, 41, 42, 43, 43 | N.S. 26 | ↑ then ↓ 44 ↓78 N.S. 44, 81 | ↑31, 35, 36, 38 | ↑ 31, 34, 38 |
| CCL3/MIP-1α | ↑ | ↑ | N.S. | ↑ 48 N.S. 48 | ↑37, 38, 43, 43 | N.S. 26 | N.S. 44 | ↑38 N.S. 35 | ↑ 38 | ||
| CCL4/MIP-1β | ↑ | ↑ | N.S. | ↑45 | ↑36, 38, 42, 43 N.S. 37, 42, 43 | ↑ 36, 38 | ↑ 38 | ||||
| CCL5/RANTES | ↑ | ↑ | N.S. | ↑45 | ↑37, 38, 42, 43, 43 | N.S. 26 | ↑81 | ↑38 N.S. 35 | N.S. 38 | ||
| CCL11/eotaxin | N.D. | N.D. | N.D. | ↑ 48 N.S. 48 | ↑38, 43, 43 | ↑ then ↓ 44 ↓ 44 | ↑ 35, 38 | ↑ 38 | |||
| CXCL1/KC | ↑ | ↑ | N.S. | ↑45 | N.S. 44 | ||||||
| G-CSF | N.S. | ↑ | N.S. | ↑45 | ↑36, 37, 38, 42, 43, 43 | N.S. 78 | ↑ 36, 38 | ↑ 38 | |||
| GM-CSF | N.D. | N.D. | N.D. | ↑ 48 N.S. 48 | ↑42, 43 ↓ 36 N.S. 37, 38, 42, 43 | ↑ then ↓ 44 N.S. 44 | ↑ 36 N.S. 38 | N.S. 38 | |||
Numbers in the table indicate the reference numbers. Statistical analysis between the uninfected mice and infected mice was not performed in the study described in reference 47. The study described in reference 45 analyzed both resistant and susceptible mice, but this table shows only the data from the susceptible mice. IU, idiopathic uveitis; N.D., significant levels were not detected; N.S., not significant; ↑, increased; ↓, decreased.
* IL-12.
** TNF.
***IL-17.
† IL-1.
‡ Increase that failed to reach statistical significance.
§ Reactivation model (data from only susceptible mice)/recurrent.
ǁ Only 1 patient out of 27 detected.
# AIDS/HIV-infected patients.